Argenica Advances Preparations for Late-Stage Stroke Drug Trial
AGN: $0.115 +9.52% · MC: $15M
Argenica Therapeutics is preparing a Phase 2b trial of xaranetide in patients with moderate to severe ischaemic stroke, with drug manufacturing and trial design work underway. It plans to present the trial strategy and seek US regulatory feedback before year-end. Subsequent pharmacology studies strengthened evidence that the drug acts on multiple injury pathways. The company reported cash reserves of approximately $5 million at the end of September.

Comments